文献速递前列腺癌

同步低体积转移性去势敏感性前列腺癌中预测前列腺定向治疗获益的基因组生物标志物

Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-08-08

单中心回顾性研究纳入101例同步低体积转移性去势敏感性前列腺癌(mCSPC)患者,中位随访44个月,按高风险(HiRi)基因组突变(TP53、ATM、BRCA1、BRCA2或Rb1致病突变)分类。HiRi突变患者接受与未接受前列腺定向治疗(PDT)的中位总生存(OS)为66.8个月 vs 73个月(p=0.3);无HiRi突变患者未接受与接受PDT的中位OS为60个月 vs 105.3个月(p<0.001),交互作用p<0.001。

要点

  • 49%的同步低体积mCSPC患者携带HiRi致病突变。
  • 无HiRi突变者接受PDT中位OS 105.3个月 vs 未接受60个月(p<0.001)。
  • HiRi突变者接受PDT与未接受中位OS无显著差异(73 vs 66.8个月,p=0.3)。

核心结论

  • HiRi基因组生物标志物似乎可预测同步低体积mCSPC男性缺乏PDT获益,需进一步工作验证这些结果。

研究设计与样本

  • 单机构回顾性综述,纳入101例接受肿瘤DNA panel测序的同步低体积mCSPC男性,中位随访44个月。

主要发现

  • HiRi突变患者未接受PDT vs 接受PDT的中位OS为66.8个月 vs 73个月(p=0.3)。
  • 无HiRi突变患者未接受PDT vs 接受PDT的中位OS为60个月 vs 105.3个月(p<0.001)。
  • PDT与HiRi突变之间OS交互作用p值有统计学意义(p<0.001)。

关键数值与推荐

  • HiRi突变定义为TP53、ATM、BRCA1、BRCA2或Rb1致病突变。
  • 约半数患者(49%)存在HiRi致病突变。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 局限性包括研究的回顾性性质。
  • 需进一步工作验证这些结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Standard of care management for synchronous metastatic castration-sensitive prostate cancer (mCSPC) includes androgen deprivation therapy with a second-generation antiandrogen therapy and/or docetaxel. Recently, randomized data have demonstrated that prostate-directed therapy (PDT) is associated with an improvement in overall survival (OS) among patients with low-volume metastatic disease. Tumor genomics represents an additional dimension to define the clinical trajectory of patients with mCSPC. OBJECTIVE: To evaluate a high-risk (HiRi) genomic signature to predict the benefit from PDT. DESIGN, SETTING, AND PARTICIPANTS: We performed a single-institution retrospective review of men with synchronous low-volume mCSPC who underwent DNA panel sequencing of their tumor. Patients were classified according to the presence of HiRi mutation including pathogenic mutations in TP53, ATM, BRCA1, BRCA2, or Rb1. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was to determine the effect of PDT on OS in patients with and without a HiRi mutation. A survival analysis was performed with the Kaplan-Meier method compared with log-rank test and multivariable Cox regression. The interaction between HiRi mutation and PDT was evaluated. RESULTS AND LIMITATIONS: A total of 101 patients with synchronous low-volume CSPC were included with a median follow-up of 44 mo. Approximately half of patients were found to have a HiRi pathogenic mutation (49%). Patients with HiRi mutations demonstrated median OS of 73 versus 66.8 mo (p = 0.3) for no PDT versus PDT. Conversely, patients without a HiRi mutation demonstrated a significant improvement in OS of 60 versus 105.3 mo (p < 0.001) for no PDT versus PDT. The p value for interaction for OS between PDT and HiRi mutation was statistically significant (p < 0.001). Limitations include the retrospective nature of the study. CONCLUSIONS: Here, we have identified a HiRi genomic biomarker that appears predictive for the lack of benefit from PDT in men with synchronous low-volume mCSPC. Further work validating these results is warranted. PATIENT SUMMARY: In this report, we evaluated a high-risk genomic biomarker to predict the benefit from prostate-directed therapy for men with synchronous low-volume metastatic castration-sensitive prostate cancer. We found that men without a high-risk mutation appear to experience a greater clinical benefit from prostate-directed therapy than those with a high-risk mutation.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sutera P, Shetty AC, Song Y, et al. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol. 2023. PMID: 37558543. doi:10.1016/j.euo.2023.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。